middle.news
Nyrada Secures $8.25M to Propel Xolatryp Phase IIa Heart Attack Trial
9:14am on Monday 4th of August, 2025 AEST
•
Healthcare
Read Story
Nyrada Secures $8.25M to Propel Xolatryp Phase IIa Heart Attack Trial
9:14am on Monday 4th of August, 2025 AEST
Key Points
Raised $8.25 million via placement at $0.30 per CDI
Funds to support Phase IIa clinical trial for Xolatryp in heart attack patients
Placement includes participation from directors, pending shareholder approval
Canary Capital acted as lead manager, receiving fees partly in CDIs and options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE